Jonathan S. Schor

Jonathan S. Schor

Auto-generated profile, based on publicly available information

Jonathan S. Schor

Neuroscience Program, University of California, San Francisco

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014
Verified
Book Chapter
Closed access
PDF file
EEEyrun Eyjolfsdottir
Eyrun Eyjolfsdottir
SBSteve Branson
Steve Branson
XBXavier Paolo Burgos-Artizzu
Xavier Paolo Burgos-Artizzu
EHEric D. Hoopfer
Eric D. Hoopfer
JSJonathan Schor
Jonathan Schor
PPPietro Perona
Pietro Perona

4 July 2022 in eLife
Verified
Journal Article
Open access
JSJonathan S Schor
Jonathan S Schor
IMIsabelle Gonzalez Montalvo
Isabelle Gonzalez Montalvo
PSPerry We Spratt
Perry We Spratt
RBRea J Brakaj
Rea J Brakaj
JSJasmine A Stansil
Jasmine A Stansil
ANAlexandra Nelson
Alexandra Nelson
Subthalamic nucleus deep brain stimulation (STN DBS) relieves many motor symptoms of Parkinson’s disease (PD), but its underlying therapeutic mechanisms remain unclear. Since its advent, three major theories have been proposed: (1) DBS inhibits the STN and basal ganglia output; (2) DBS antidromically activates motor cortex; and (3) DBS disrupts firing dynamics within the STN. Previously, stimulation-related electrical artifacts limited mechanistic investigations using electrophysiology. We used electrical artifact-free GCaMP fiber photometry to investigate activity in basal ganglia nuclei during STN DBS in parkinsonian mice. To test whether the observed changes in activity were sufficient to relieve motor symptoms, we then combined electrophysiological recording with targeted optical DBS protocols. Our findings suggest that STN DBS exerts its therapeutic effect through the disruption of movement-related STN activity, rather than inhibition or antidromic activation. These results provide insight into optimizing PD treatments and establish an approach for investigating DBS in other neuropsychiatric conditions.

12 August 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JSJonathan S. Schor
Jonathan S. Schor
ANAlexandra Nelson
Alexandra Nelson
Deep brain stimulation (DBS) is used to treat multiple neuropsychiatric disorders, including Parkinson’s disease (PD). Despite widespread clinical use, its therapeutic mechanisms are unknown. Here, we developed a mouse model of subthalamic nucleus (STN) DBS for PD, to permit investigation using cell type–specific tools available in mice. We found that electrical STN DBS relieved bradykinesia, as measured by movement velocity. In addition, our model recapitulated several hallmarks of human STN DBS, including rapid onset and offset, frequency dependence, dyskinesia at higher stimulation intensity, and associations among electrode location, therapeutic benefit, and side effects. We used this model to assess whether high-frequency stimulation is necessary for effective STN DBS and whether low-frequency stimulation can be effective when paired with compensatory adjustments in other parameters. We found that low-frequency stimulation, paired with greater pulse width and amplitude, relieved bradykinesia. Moreover, a composite metric incorporating pulse width, amplitude, and frequency predicted therapeutic efficacy better than frequency alone. We found a similar relationship between this composite metric and movement speed in a retrospective analysis of human data, suggesting that correlations observed in the mouse model may extend to human patients. Together, these data establish a mouse model for elucidating mechanisms of DBS.

27 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JEJordan L. Edmunds
Jordan L. Edmunds
MBMauricio J. Bustamante
Mauricio J. Bustamante
DPDavid K. Piech
David K. Piech
JSJonathan S. Schor
Jonathan S. Schor
SRSamuel J. Raymond
Samuel J. Raymond
MMMichel M. Maharbiz
Michel M. Maharbiz
A bstract: COVID-19 has become a significant burden on the healthcare systems in the United States and around the world, with many patients requiring invasive mechanical ventilation (IMV) to survive. Close monitoring of patients is critical, with total volume per breath (tidal volume) being one of the most important data points. However, ventilators are complex and expensive devices, typically in the range of tens of thousands of US dollars, and are challenging to manufacture, typically requiring months. Solutions which could augment the ventilator supply rapidly and at low cost in the United States and elsewhere would be valuable. In this paper, we present a standalone tidal volume measurement system consisting of a D-Lite spirometer, pressure sensor, microcontroller, and tubing with a cost of parts less than $50 USD. We also provide a model to predict the error in tidal volume measurements based on the pressure sensor used and the flow during ventilation. We validate this system and show that the tidal volume accuracy for flows above 10 L / min was within 10%. We envision this system being used to increase the ventilator supply in resource-constrained settings.